Aesthetic Medical International Holdings Group Ltd — Cyborg Score 4/10
Weak
Aesthetic and cosmetic medical services
Strategic Profile
The company derives a majority of its revenue from non-surgical aesthetic medical services. The company transitioned to OTCQX Best Market trading in July 2024, signaling improved disclosure and governance standards for a China-based aesthetic medical services provider targeting Chinese consumers.
Cyborg Score Rationale
As of April 2025, the company had a market capitalization of $7.17M against trailing 12-month revenue of $103M, indicating severe valuation compression. The company trades on OTC markets with limited liquidity and faces typical challenges of China-exposed healthcare providers with regulatory and cross-border compliance risks.
Top Insights
Revenue grew 10.71% to $755.67M in 2024, while losses improved 46.72% to -$19.95M compared to 2023
Non-surgical aesthetic services drive majority revenue, aligning with market trend toward less invasive procedures
OTCQX listing in July 2024 provides greater transparency but reflects limited institutional investor appeal
Valuation disconnect: $7.17M market cap on $103M revenue suggests severe investor skepticism regarding China regulatory environment and capital repatriation risks
Named Competitors
Hangzhou Meitu Technology — Online aesthetic medicine marketplace in China
Beauty clinics and medical spas — Local aesthetic medical providers across Chinese cities
Recent Developments
(July 2024) Transitioned to OTCQX Best Market trading from OTC Pink market
(April 2026) Most recent SEC filing submitted on April 3, 2026
(2024) Revenue reached $755.67M with 10.71% year-over-year growth
Open the full interactive Aesthetic Medical International Holdings Group Ltd report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.